Browsing by title

E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium.

Horne, HN; Oh, H; Sherman, ME; Palakal, M; Hewitt, SM; Schmidt, MK; Milne, RL; Hardisson, D; Benitez, J; Blomqvist, C; Bolla, MK; Brenner, H; Chang-Claude, J; Cora, R; Couch, FJ; Cuk, K; Devilee, P; Easton, DF; Eccles, DM; Eilber, U; Hartikainen, JM; Heikkilä, P; Holleczek, B; Hooning, MJ; Jones, M; Keeman, R; Mannermaa, A; Martens, JWM; Muranen, TA; Nevanlinna, H; Olson, JE; Orr, N; Perez, JIA; Pharoah, PDP; Ruddy, KJ; Saum, K-U; Schoemaker, MJ; Seynaeve, C; Sironen, R; Smit, VTHBM; Swerdlow, AJ; Tengström, M; Thomas, AS; Timmermans, AM; Tollenaar, RAEM; Troester, MA; van Asperen, CJ; van Deurzen, CHM; Van Leeuwen, FF; Van't Veer, LJ; García-Closas, M; Figueroa, JD (2018-04-26)

E-cadherin (CDH1) is a putative tumor suppressor gene implicated in breast carcinogenesis. Yet, whether risk factors or survival differ by E-cadherin tumor expression is unclear. We evaluated E-cadherin tumor immunohistochemistry ...

E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer.

Bajrami, I; Marlow, R; van de Ven, M; Brough, R; Pemberton, HN; Frankum, J; Song, F; Rafiq, R; Konde, A; Krastev, DB; Menon, M; Campbell, J; Gulati, A; Kumar, R; Pettitt, SJ; Gurden, MD; Cardenosa, ML; Chong, I; Gazinska, P; Wallberg, F; Sawyer, EJ; Martin, L-A; Dowsett, M; Linardopoulos, S; Natrajan, R; Ryan, CJ; Derksen, PWB; Jonkers, J; Tutt, ANJ; Ashworth, A; Lord, CJ (2018-04)

The cell adhesion glycoprotein E-cadherin (CDH1) is commonly inactivated in breast tumors. Precision medicine approaches that exploit this characteristic are not available. Using perturbation screens in breast tumor cells ...

An E2-ubiquitin thioester-driven approach to identify substrates modified with ubiquitin and ubiquitin-like molecules.

Bakos, G; Yu, L; Gak, IA; Roumeliotis, TI; Liakopoulos, D; Choudhary, JS; Mansfeld, J (2018-11-14)

Covalent modifications of proteins with ubiquitin and ubiquitin-like molecules are instrumental to many biological processes. However, identifying the E3 ligase responsible for these modifications remains a major bottleneck ...

EANM practical guidance on uncertainty analysis for molecular radiotherapy absorbed dose calculations.

Gear, JI; Cox, MG; Gustafsson, J; Gleisner, KS; Murray, I; Glatting, G; Konijnenberg, M; Flux, GD (2018-12)

A framework is proposed for modelling the uncertainty in the measurement processes constituting the dosimetry chain that are involved in internal absorbed dose calculations. The starting point is the basic model for absorbed ...

EANM/EARL FDG-PET/CT accreditation - summary results from the first 200 accredited imaging systems.

Kaalep, A; Sera, T; Oyen, W; Krause, BJ; Chiti, A; Liu, Y; Boellaard, R (2018-03)

PURPOSE:From 2010 until July 2016, the EANM Research Ltd. (EARL) FDG-PET/CT accreditation program has collected over 2500 phantom datasets from approximately 200 systems and 150 imaging sites worldwide. The objective of ...

Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer.

O'Leary, B; Hrebien, S; Morden, JP; Beaney, M; Fribbens, C; Huang, X; Liu, Y; Bartlett, CH; Koehler, M; Cristofanilli, M; Garcia-Murillas, I; Bliss, JM; Turner, NC (2018-03)

CDK4/6 inhibition substantially improves progression-free survival (PFS) for women with advanced estrogen receptor-positive breast cancer, although there are no predictive biomarkers. Early changes in circulating tumor DNA ...

Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial.

Hrebien, S; Citi, V; Garcia-Murillas, I; Cutts, R; Fenwick, K; Kozarewa, I; McEwen, R; Ratnayake, J; Maudsley, R; Carr, TH; de Bruin, EC; Schiavon, G; Oliveira, M; Turner, N (2019-06)

<h4>Background</h4>Dynamic changes in circulating tumour DNA (ctDNA) levels may predict long-term outcome. We utilised samples from a phase I/II randomised trial (BEECH) to assess ctDNA dynamics as a surrogate for ...

Early enrichment of ESR1 mutations and the impact on gene expression in pre-surgical primary breast cancer treated with aromatase inhibitors.

Leal, MF; Haynes, BP; Schuster, EF; Yeo, B; Afentakis, M; Zabaglo, L; Martins, V; Buus, R; Dodson, A; Cheang, MCU; Smith, IE; Martin, L-A; Dowsett, M (2019-09-23)

PURPOSE: To investigate the presence of ESR1 mutation in primary oestrogen-receptor positive breast cancer (ER+BC) treated with extended (>4 weeks) neoadjuvant (pre-surgical) aromatase inhibitor (NAI) therapy and to identify ...

Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors.

Leal, MF; Haynes, BP; Schuster, E; Yeo, B; Afentakis, M; Zabaglo, L; Martins, V; Buus, R; Dodson, A; Cheang, MCU; Smith, IE; Martin, L-A; Dowsett, M (2019-12)

PURPOSE:To investigate the presence of ESR1 mutations in primary estrogen-receptor-positive (ER+) breast cancer treated with extended (>4 weeks) neoadjuvant (presurgical) aromatase inhibitor (NAI) therapy and to identify ...

Early enrichment of ESR1 mutations and the impact on gene expression in primary breast cancer treated with aromatase inhibitors in the pre-surgical setting

Dowsett, M; Ferreira Leal, M; Haynes, B; Schuster, E; Yeo, B; Afentakis, M; Zabaglo, L; Martins, V; Buus, R; Dodson, A; Cheang, M; Smith, I; Martin, L-A

Early growth response 2 regulates the survival of thymocytes during positive selection

Lawson, VJ; Weston, K; Maurice, D (WILEY-V C H VERLAG GMBH, 2010-01)

The early growth response (Egr) transcription factor family regulates multiple steps during T-cell development. We examine here the role played by Egr2 in positive selection. in double-positive cells, Egr2 is upregulated ...

Early phase clinical trials of anticancer agents in children and adolescents - an ITCC perspective.

Moreno, L; Pearson, ADJ; Paoletti, X; Jimenez, I; Geoerger, B; Kearns, PR; Zwaan, CM; Doz, F; Baruchel, A; Vormoor, J; Casanova, M; Pfister, SM; Morland, B; Vassal, G; Innovative Therapies for Children with Cancer (ITCC) Consortium (2017-08)

In the past decade, the landscape of drug development in oncology has evolved dramatically; however, this paradigm shift remains to be adopted in early phase clinical trial designs for studies of molecularly targeted agents ...

Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis.

Rescigno, P; Dolling, D; Conteduca, V; Rediti, M; Bianchini, D; Lolli, C; Ong, M; Li, H; Omlin, AG; Schmid, S; Caffo, O; Zivi, A; Pezaro, CJ; Morley, C; Olmos, D; Romero-Laorden, N; Castro, E; Saez, MI; Mehra, N; Smeenk, S; Sideris, S; Gil, T; Banks, P; Sandhu, SK; Sternberg, CN; De Giorgi, U; De Bono, JS (2020-04)

<h4>Background</h4>Declines in prostate-specific antigen (PSA) levels at 12wk are used to evaluate treatment response in metastatic castration-resistant prostate cancer (mCRPC). PSA fall by ≥30% at 4wk (PSA4w30) has been ...

Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma.

Bygrave, C; Pawlyn, C; Davies, F; Craig, Z; Cairns, D; Hockaday, A; Jenner, M; Cook, G; Drayson, M; Owen, R; Gregory, W; Morgan, G; Jackson, G; Kaiser, M (2020-06-10)

Predicting patient outcome in multiple myeloma remains challenging despite the availability of standard prognostic biomarkers. We investigated outcome for patients relapsing early from intensive therapy on NCRI Myeloma XI. ...

Ecdysone-inducible expression of oncogenic Ha-Ras in NIH 3T3 cells leads to transient nuclear localization of activated extracellular signal-regulated kinase regulated by mitogen-activated protein kinase phosphatase-1.

Plows, D; Briassouli, P; Owen, C; Zoumpourlis, V; Garrett, MD; Pintzas, A (2002-03)

The Ras family of GTP-binding proteins are key transducers of extracellular signals, particularly through the mitogen-activated protein kinase (MAPK) pathway. Constitutively active forms of Ras are found in a variety of ...

Publications Repository

Publications Repository